Thus, function blocking antibodies and peptides to CD47 or its receptor SIRPα induce macrophage phagocytosis of live cancer cells in culture and in vivo, and are being developed as a potential treatment for multiple cancers (322, 324). Here, CD47 is linked to cancer.